#Clinilabs is proud to have collaborated with eight researchers from leading academic medical centers in the US and Europe, Idorsia Pharmaceuticals Ltd, and Beacon Biosignals on the recent publication featured in SLEEP entitled: “Effect of daridorexant on sleep architecture in patients with chronic insomnia disorder - A pooled post hoc analysis of two randomized Phase 3 [...]
Clinilabs Events Join us for two exciting events at the ASENT meeting! Gary K. Zammit, PhD will be participating in the ASENT Training in Clinical Trials course Panel of Successful Trialists before the ASENT meeting. Overview: This panel discussion will introduce researchers and clinicians to the principles of neurotherapeutic clinical trial development and implementation and [...]
Join us at World Sleep Society's Annual event from October 20th - October 25th in Rio de Janeiro, Brazil. This event will feature an exciting program of scientific presentations, courses, and social events dedicated to advancing sleep health worldwide. Come meet with us and find out how we can be your clinical trial partner. Dr. [...]
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™”, and its partner Clinilabs Drug Development Corporation (“Clinilabs”), a global, full-service contract research organization with deep expertise in central nervous system drug development, today announced that the U.S. Drug Enforcement Agency (“DEA”) has granted a Schedule I license [...]
EATONTOWN, N.J.--(BUSINESS WIRE)--Clinilabs Drug Development Corporation (“Clinilabs”), a global, full-service contract research organization with deep expertise in central nervous system drug development, announced today that enrollment has begun in a Phase 1/2a clinical trial of CYB003, the first novel psilocybin analog to be evaluated in Phase 1/2a development for the treatment of major depressive disorder (“MDD”). [...]
April 21, 2022 12:00 UTC TORONTO--(BUSINESS WIRE)-- Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM”, today announced that it has partnered with Clinilabs Drug Development Corporation (“Clinilabs”), a global, full-service contract research organization with deep expertise in central nervous system drug development, to carry out the Company’s Phase 1/2a clinical trial of [...]
Pharmaceutical companies have used experimental models of transient insomnia to assess the sleep-promoting effects of investigational drugs for over 40 years. These models have included the "first-night effect" model, a parallel-group design that assessed drug effects when sleep was recorded in normal, healthy subjects who slept in a new or novel environment for the [...]
Clinilabs and the DTRA Aim to Dramatically Increase Access for All Patient Populations in Clinical Trials and Research June 7, 2021 – Clinilabs Drug Development Corporation joins a historic alliance of over one hundred life science and healthcare organizations that seek to accelerate the broad adoption of patient-focused, decentralized clinical trials and research. The “Decentralized [...]
Clinilabs congratulates Larimar Therapeutics Inc. on their Topline Phase 1 Clinical Trial Data in patients with Friedreich’s Ataxia! We are proud to have been part of this clinical trial and to have worked with this partner who is dedicated to bringing life changing treatments to patients with this rare disease. To learn more about [...]
2020 will go down as a miserable year, but beyond the heartache, some developments may represent bright spots that light the way to the future. One of these is the growth of Decentralized Clinical Trials (DCTs). DCTs are virtual trials that integrate remote assessments with modern digital health technologies, including remote rating apps, wearable monitoring [...]
